IRIS
DE LUCA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.004
NA - Nord America 2.940
EU - Europa 2.552
SA - Sud America 783
AF - Africa 56
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.341
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.829
SG - Singapore 1.177
CN - Cina 944
RO - Romania 699
BR - Brasile 671
SE - Svezia 471
IT - Italia 470
HK - Hong Kong 423
DE - Germania 255
VN - Vietnam 183
RU - Federazione Russa 141
FI - Finlandia 105
GB - Regno Unito 97
CA - Canada 64
AT - Austria 57
IN - India 54
FR - Francia 53
NL - Olanda 53
AR - Argentina 52
JP - Giappone 48
PL - Polonia 39
MX - Messico 37
ZA - Sudafrica 29
ES - Italia 27
TR - Turchia 24
ID - Indonesia 22
BD - Bangladesh 20
PH - Filippine 20
EC - Ecuador 18
LT - Lituania 16
UA - Ucraina 14
AE - Emirati Arabi Uniti 11
IQ - Iraq 11
PK - Pakistan 11
UZ - Uzbekistan 11
VE - Venezuela 11
CO - Colombia 10
IE - Irlanda 10
PY - Paraguay 10
BE - Belgio 8
KR - Corea 8
IR - Iran 7
PE - Perù 7
EG - Egitto 6
NO - Norvegia 6
AZ - Azerbaigian 5
LU - Lussemburgo 5
MA - Marocco 5
MK - Macedonia 5
TN - Tunisia 5
BH - Bahrain 4
XK - ???statistics.table.value.countryCode.XK??? 4
BG - Bulgaria 3
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IL - Israele 3
KZ - Kazakistan 3
PT - Portogallo 3
BY - Bielorussia 2
CH - Svizzera 2
EU - Europa 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
JO - Giordania 2
KE - Kenya 2
LV - Lettonia 2
MN - Mongolia 2
MY - Malesia 2
SA - Arabia Saudita 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GA - Gabon 1
HR - Croazia 1
JM - Giamaica 1
LB - Libano 1
MD - Moldavia 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
UY - Uruguay 1
Totale 9.341
Salva come PNG Salva come JPEG
Città #
Dallas 1.100
Singapore 592
Hong Kong 420
Ashburn 318
Shanghai 247
Beijing 166
Hefei 156
New York 141
Milan 127
Lawrence 99
Princeton 99
Los Angeles 98
Munich 96
São Paulo 73
Ho Chi Minh City 72
Moscow 72
Boardman 63
Nuremberg 61
Helsinki 59
Rome 39
Tokyo 38
Warsaw 35
Hanoi 32
Denver 29
Atlanta 28
Santa Clara 28
Montreal 27
Rio de Janeiro 27
Turku 27
Johannesburg 25
Cesano Boscone 23
Poplar 23
Frankfurt am Main 22
Guangzhou 22
Stockholm 22
Chicago 21
Chennai 20
Falkenstein 19
Lappeenranta 18
Orem 17
Vienna 17
Ankara 16
Brooklyn 16
Mexico City 16
London 15
Houston 14
Amsterdam 13
Seattle 13
Manchester 12
The Dalles 12
Boston 11
Buffalo 11
Campinas 11
Naples 11
Secaucus 11
Shenzhen 11
Belo Horizonte 10
City of London 10
Dublin 10
Haiphong 10
Phoenix 10
Tashkent 10
Tianjin 10
Toronto 10
Xi'an 10
Makati City 9
Mumbai 9
Porto Alegre 9
Brasília 8
Brussels 8
Seongnam-si 8
Verona 8
Biên Hòa 7
Can Tho 7
Curitiba 7
Guayaquil 7
Marília 7
New Delhi 7
Padua 7
Pune 7
San Francisco 7
San Jose 7
Ancona 6
Columbus 6
Hangzhou 6
Istanbul 6
Lima 6
Manaus 6
Natal 6
Osaka 6
Oslo 6
Querétaro 6
Recife 6
Romagnano Sesia 6
Roubaix 6
Zhengzhou 6
Baghdad 5
Baie-D'Urfé 5
Baku 5
Brescia 5
Totale 5.134
Salva come PNG Salva come JPEG
Nome #
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 419
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 382
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 325
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 320
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 208
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 161
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 133
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 109
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 108
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 107
B cells in systemic sclerosis: A possible target for therapy 98
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 95
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 94
Arrhythmias in Myocarditis: State of the Art 86
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 86
A Novel Histiocytosis With Synovial and Skin Involvement 82
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 81
C3-glomerulopathy and MGUS: The skin beyond the kidney 81
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 80
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 80
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 80
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 78
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 78
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 78
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 77
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 76
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 75
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 74
Pruritus characteristics in a large Italian cohort of psoriatic patients 74
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 73
Advances in potential targeted therapies for Erdheim-Chester disease 72
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 72
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 71
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 70
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 70
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 69
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 68
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 67
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 66
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 66
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 66
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 66
Therapeutic strategies for primary heart involvement in systemic sclerosis 65
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 65
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 65
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 65
Drug retention rates of biological agents in adult onset Still's disease 65
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 65
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 64
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 64
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 63
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 63
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 62
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 62
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 60
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 59
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 59
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 59
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 58
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 58
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 58
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 57
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 57
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 56
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 56
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 56
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 56
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 56
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 54
Cardiovascular magnetic resonance parametric mapping in the risk stratification of patients affected by chronic myocarditis 54
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 53
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 53
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 52
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic 52
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 52
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 51
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 50
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 50
Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation 50
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 50
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 50
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 50
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 49
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 48
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 47
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 47
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 46
Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report 46
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 46
Data standards for transcatheter aortic valve implantation: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) (October, qcac063, 2022) 43
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 43
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 43
Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging 43
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 43
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 42
Therapeutic strategies for virus-negative myocarditis: a comprehensive review 42
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 42
Pain and Frailty in Hospitalized Older Adults 41
Myocarditis: An Interleukin-1-Mediated Disease? 41
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review 41
Totale 7.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.814
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.814
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 12 8 3 1 0 4 2
2021/2022249 1 0 102 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024744 25 56 75 67 65 111 42 82 5 33 36 147
2024/20253.364 224 41 102 104 130 218 1.093 331 388 233 200 300
2025/20264.495 612 868 944 1.147 707 217 0 0 0 0 0 0
Totale 9.723